We are live on ! Find out more
TCRT icon

Alaunos Therapeutics
TCRT

82 hedge funds and large institutions have $2.97M invested in Alaunos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more call options, than puts

Call options by funds: $20K | Put options by funds: $2K

0.04% less ownership

Funds ownership: 0.16% → 0.11% (-0.04%)

8% less funds holding

Funds holding: 89 → 82 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

60% less capital invested

Capital invested by funds: $7.36M → $2.97M (-$4.39M)

60% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 25

Holders
82
Holders Change
-7
Holders Change %
-7.87%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
10
Reduced
25
Closed
15
Calls
$20K
Puts
$2K
Net Calls
+$18K
Net Calls Change
-$1.04M

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$35.8K
2
Renaissance Technologies
Renaissance Technologies
New York
+$30.7K
3
Morgan Stanley
Morgan Stanley
New York
+$13K
4
TSS
Two Sigma Securities
New York
+$10.7K
5
Millennium Management
Millennium Management
New York
+$8.09K

Top Sellers

Rank Fund Capital Flow
1
DCM
Discovery Capital Management
Connecticut
-$920K
2
BC
Boxer Capital
California
-$145K
3
BlackRock
BlackRock
New York
-$131K
4
GCP
GSA Capital Partners
United Kingdom
-$75K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$31.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$7.12K +$8.09K +672 New
William Blair & Company
27
William Blair & Company
Illinois
$6.63K – – –
PAG
28
Private Advisor Group
New Jersey
$4.79K -$2.25K -187 -29%
CCM
29
Chiron Capital Management
Florida
$4.75K -$783 -65 -13%
SWM
30
Sugarloaf Wealth Management
Georgia
$4.63K -$795 -66 -13%
Bank of America
31
Bank of America
North Carolina
$4.04K +$48 +4 +1%
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$4K +$241 +20 +6%
Cerity Partners
33
Cerity Partners
New York
$3.86K +$48 +4 +1%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$3.67K -$241 -20 -5%
RWMG
35
Redwood Wealth Management Group
New Jersey
$3.54K +$4.02K +334 New
CIBC Private Wealth Group
36
CIBC Private Wealth Group
Georgia
$3.54K -$36 -3 -0.9%
WG
37
Welch Group
Alabama
$3.04K – – –
Janney Montgomery Scott
38
Janney Montgomery Scott
Pennsylvania
$3K -$2.02K -168 -38%
AF
39
Advisornet Financial
Minnesota
$2.99K – – –
SF
40
Synovus Financial
Georgia
$2.9K – – –
NAS
41
Nicolet Advisory Services
Wisconsin
$2.82K – – –
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$2.78K – – –
Two Sigma Advisers
43
Two Sigma Advisers
New York
$2.62K -$31.7K -2,628 -91%
CPIG
44
Chicago Partners Investment Group
Illinois
$2.6K – – –
HKAM
45
Horizon Kinetics Asset Management
New York
$2.4K – – –
MA
46
Mutual Advisors
Nebraska
$1.92K – – –
SPIA
47
Steward Partners Investment Advisory
New York
$1.85K – – –
Creative Planning
48
Creative Planning
Kansas
$1.81K +$72 +6 +4%
STA
49
Summit Trail Advisors
New York
$1.79K – – –
LPL Financial
50
LPL Financial
California
$1.66K +$1.88K +156 New
1
2
3 4

TCRT Hedge Fund Activity: Q4 2023 in Review

82 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2023, worth a combined $2.97M — down 60% from $7.36M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TCRT and 8 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 10 added.

The largest buyer was Squarepoint, opening a new position worth an estimated $35.8K. The largest seller was Discovery Capital Management, cutting an estimated $920K.

  • 82 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2023, down from 89 in Q3 2023.
  • Funds reported $2.97M of Alaunos Therapeutics stock for Q4 2023, down 60% quarter-over-quarter.
  • 8 funds opened new Alaunos Therapeutics positions in Q4 2023 and 15 closed out, a net change of -7 holders.
  • The largest Alaunos Therapeutics buyer in Q4 2023 was Squarepoint, an estimated $35.8K added.
  • The largest Alaunos Therapeutics seller in Q4 2023 was Discovery Capital Management, an estimated $920K sold.

Based on aggregated 13F filings for Q4 2023.